Michael Jeng

Professor of Pediatrics (Hematology/Oncology)

Clinical Focus

Hematology, Pediatric
Vascular anomalies
Histiocytic disorders
Langerhans cell histiocytosis
Hemophagocytic Lymphohistiocytosis
Pediatric Hematology-Oncology

Academic Appointments

Professor - University Medical Line, Pediatrics - Hematology & Oncology
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute

Administrative Appointments

Interim Division Chief, Pediatric Hematology/Oncology, Stanford University School of Medicine (2017 - 2018)
Fellowship Program Director, Pediatric Hematology/Oncology, Stanford University School of Medicine (2016 - 2021)
Bass Center Inpatient Medical Director, Lucile Packard Children's Hospital Stanford (2014 - 2016)
Chair, Pharmacy and Therapeutics Committee, Lucile Packard Children's Hospital (2005 - 2013)

Honors & Awards

Dr. Marion Koerper Award for Medical Excellence, Hemophilia Foundation of Northern California (2009)
St. Jude Teaching Award, LeBonheur Children's Hospital (2002)

Boards, Advisory Committees, Professional Organizations

Board of Directors, American Society of Pediatric Hematology Oncology (2022 - Present)
Editorial Board, Pediatric Hematology Oncology (2019 - Present)
Chair, Training Committee, American Society of Pediatric Hematology Oncology (ASPHO) (2018 - 2020)
Associate Editor, Pediatric Research (2017 - Present)
Practice Committee, American Society of Pediatric Hematology Oncology (ASPHO) (2010 - 2016)

Professional Education

Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2000)
Fellowship: UCSF Pediatric Hematology/Oncology Fellowship (1999) CA
Residency: Children's Memorial Hospital (1996) IL
Medical Education: Case Western Reserve School of Medicine (1993) OH
B.A., Bowdoin College, Biology, Philosophy (1989)

Community and International Work

Hemophilia Camp Medical Volunteer

Topic

Partnering Organization(s)

Hemophilia Foundation of Northern California

Populations Served

Location

Bay Area

Ongoing Project

true

Opportunities for Student Involvement

true

Contact

Academic Tel: (650) 723-5535Tel: (650) 736-1177 Fax: (650) 723-5231

Administrative Contact Xitlali Jimenez Admin Assoc xitlalli@stanford.edu Tel: 650-723-5535

Clinical San Francisco Orthopedics and Sports Medicine Clinic 1100 Van Ness 7th Fl San Francisco CA 94109 Tel: (844) 733-2762 Fax: (650) 725-7578
Clinical Pediatric Hematology and Oncology 770 Welch Rd Ste 261 Palo Alto CA 94304
Clinical Pediatric Hematology and Oncology 725 Welch Rd Palo Alto CA 94304 Tel: (650) 497-8953 Fax: (650) 725-3219

Current Research and Scholarly Interests

Research interests focus on the clinical care and treatment of children with disorders in 2 clinical areas 1) histiocytic disorders, such as Langerhans cell histiocytosis, and hemophagocytic lymphohistiocytosis, and 2) vascular anomalies and malformations.

Clinical Trials

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) Recruiting
More
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions. For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH. The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.
Lead Sponsor
Stanford Investigators
- Michael Jeng
View full details
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components Not Recruiting
More
This study is a prospective, non-randomized sequential cohort, open label, multi-center, non-inferiority, Phase IV surveillance study following transfusion of INTERCEPT PCs. The patient population will be hematology-oncology patients, including those undergoing hematopoietic stem cell transplant (HSCT), expected to require one or more PC transfusions. For each participating center, the study will start with a brief pilot run-in period with a group of at least 5 patients exposed only to conventional PCs. The purpose of this pilot run-in is to evaluate study logistics and data collection methods within each study center. Data from the pilot phase will be included in the data analysis for the treatment comparison. After the pilot run-in period, the study will be conducted in two sequential patient cohorts: 1) the Control cohort during which study patients will receive only conventional PCs, and 2) the INTERCEPT cohort during which patients will receive only INTERCEPT PCs. Patient enrollment at each Center will be monitored to target similar numbers of patients into the Control and Test Cohorts within each center. Centers may enroll Control and Test patients in ratios that vary from 2:1 to 1:2 due to institutional requirements to move rapidly to full INTERCEPT implementation, or due to availability issues with either Test or Control components. Within each Center, patient enrollment will be stratified in four categories: (1) chemotherapy only; and by use of conditioning regimens for hematopoietic stem cell transplantation (HSCT) in (2) myeloablative conditioning, (3) non-myeloablative conditioning, and (4) reduced intensity using the Center for International Blood and Marrow Transplant Research (CIBMTR) criteria. Note time from last chemotherapy treatment to first study transfusion should be no more than 30 days. To ensure both Test and Control cohorts have a similar allocation ratio (±10% per category) among the conditioning regimen strata, enrollment caps will be set for the Test cohorts, hence no Test patients will be enrolled to a stratum once the cap for the given stratum is met. Eligible patients will be enrolled in open Test strata sequentially as long as there is sufficient Test PC inventory available. Enrollment may be delayed for the Test cohort if sufficient inventory of Test PCs is not available.

Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Lead Sponsor
Stanford Investigators
- Michael Jeng
View full details
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Recruiting
More
This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.
Lead Sponsor
Stanford Investigators
- Michael Jeng
View full details
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study Recruiting
More
This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and to compare if these effects are similar to those observed in adults.
Lead Sponsor
Stanford Investigators
- Michael Jeng
View full details

2022-23 Courses

Independent Studies
- Directed Reading in Pediatrics
  PEDS 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience
  PEDS 280 (Aut, Win, Spr, Sum)
- Graduate Research
  PEDS 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  PEDS 370 (Aut, Win, Spr, Sum)
- Undergraduate Directed Reading/Research
  PEDS 199 (Aut, Win, Spr, Sum)

Stanford Advisees

Postdoctoral Faculty Sponsor
Heather Alva

Graduate and Fellowship Programs

Pediatric Hem/Onc (Fellowship Program)

All Publications

Profiles With Related Publications

close
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma
Clinical Focus
Cancer > Lymphoma, Burkitt's Lymphoma, Hodgkin's Disease, Investigational Therapeutics, Lymphoma , Mycosis Fungoides, Non-Hodgkin's Lymphoma, Oncology (Cancer), Plasmacytoma, Waldenstrom's Macroglobulinemia , Medical Oncology
Research Interests
Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

622 Total Publications
close
Ash A. Alizadeh, MD/PhD

Moghadam Family Professor
Clinical Focus
Cancer > Lymphoma, Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, Follicular Lymphoma, Diffuse Large-Cell Lymphomas, Leukemia, Hairy Cell, Lymphoma, B-Cell, Marginal Zone, Hodgkin Disease, Medical Oncology
Research Interests
My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

352 Total Publications
close
Michael Amylon

Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus
Research Interests
Bone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia.

104 Total Publications
close
William Berquist

Professor of Pediatrics (Gastroenterology)
Clinical Focus
Pediatric Gastroenterology, Ped Gastroenterology
Research Interests
Gastroenterology, gastointestinal motility, clinical management of pediatric liver transplant recipients.

107 Total Publications
close
Alice Bertaina MD, PhD

Associate Professor of Pediatrics (Stem Cell Transplantation)
Clinical Focus
Pediatric Stem Cell Transplantation, Graft engineering, Pediatric Hematology-Oncology

167 Total Publications
close
Tina Cowan

Professor of Pathology (Clinical) and, by courtesy, of Pediatrics (Genetics)
Clinical Focus
Pathology and Laboratory Medicine, Pathology
Research Interests
screening and diagnosis of patients with inborn errors of metabolism, including newborn screening, development of new testing methods and genotype/phenotype correlations.

84 Total Publications
close
Kenneth L. Cox

Professor of Pediatrics (Gastroenterology) at the Lucile Salter Packard Children's Hospital, Emeritus
Research Interests
Gastroenterology, biliary motility, hormonal regulation, embryology, gastrointestinal tract, clinical management of pediatric liver transplant recipients.

68 Total Publications
close
Kristina Patrice Cusmano-Ozog

Clinical Associate Professor, Pathology
Clinical Focus
Biochemical Genetics, Metabolism, Inborn Errors, Clinical Biochemical Genetics

34 Total Publications
close
Gary Dahl

Professor of Pediatrics (Hematology/Oncology), Emeritus
Research Interests
Hematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.

169 Total Publications
close
Carlos O. Esquivel, M.D., Ph.D.,FACS

Arnold and Barbara Silverman Professor in Pediatric Transplantation and Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Gastroenterology)
Clinical Focus
Liver Transplantation, General Surgery, Intestinal Transplantation, Pediatric LiverTransplantation, Liver cancer
Research Interests
1) Induction of immunotolerance
2) Rejection of liver and intestinal transplantation.
3) Clinical outcomes of children with unresectable liver tumors.

415 Total Publications
close
Bertil Glader

Stanford Medicine Professor of Pediatric Hematology/Oncology and Professor, by courtesy, of Pathology
Clinical Focus
Pediatric Hematology-Oncology
Research Interests
Hematology/Oncology, biology, and treatment of bone marrow failure disorders, hereditary coagulation disorders-clinical trials.

234 Total Publications
close
Lawrence Tim Goodnough

Professor of Pathology and of Medicine (Hematology)
Clinical Focus
Pathology, Transfusion Medicine
Research Interests
Improving blood utilization
Promoting alternatives to blood transfusion
Quality improvements

418 Total Publications